NCT06314685View on ClinicalTrials.gov

Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

2,450

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

August 30, 2024

Study Completion Date

August 30, 2024

Conditions
Healthy Population
Interventions
BIOLOGICAL

Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

As a experimental vaccine for 6 months to 5 years old.

BIOLOGICAL

Group A and C Meningococcal Polysaccharide Vaccine

As a control vaccine for ages 6-11 months and 12-23 months.

BIOLOGICAL

Group ACYW135 Meningococcal Polysaccharide Vaccine

As a control vaccine for ages 2-5 years.

Trial Locations (1)

410005

Hunan Center for Disease Control and Prevention, Changsha

All Listed Sponsors
lead

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

INDUSTRY